DJIA 16,677.90 216.58 1.32%
NASDAQ 4,452.79 69.95 1.60%
S&P 500 1,950.82 23.71 1.23%
market minute promo

4.61 0.05 (1.10%)

REAL-TIME: Last trade at

Extended Hours: $4.58 -$0.03 (-0.65%)
Quote as of (NASDAQ)



company name or ticker

Recent Quotes

PGNX $4.61 1.10%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $4.63
Previous Close $4.56
Daily Range $4.56 - $4.79
52-Week Range $3.10 - $7.45
Market Cap $320.7M
P/E Ratio -7.48
Dividend (Yield) $0.00 (0.0%)
Volume 645,753
Average Daily Volume 880,815
Current FY EPS -$0.01

Sector

Healthcare

Industry

Drugs

Progenics Pharmaceuticals, Inc. (PGNX) Description

A biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Website: http://www.progenics.com/

News & Commentary Rss Feed

This Week in Biotech: AbbVie's Five-Leaf Clover and Exelixis' Excellent Results

A long-awaited mega-merger is announced, Exelixis reminds Wall Street that its pipeline is more than a single compound, and Amgen shows flashes of what's coming down its pipeline.

Phase 2 Data for Progenics' 1404 Imaging Agent Presented at EANM Congress

Progenics Gets $40M Milestone on FDA Approval of Relistor - Analyst Blog

Progenics Receives $40M Milestone Following FDA Approval of RELISTOR For OIC Patients With Chronic N

Progenics Receives $40M Milestone Following FDA Approval of RELISTOR For OIC Patients With Chronic Non-Cancer Pain

Progenics/Salix's Relistor Label Expanded in the U.S. - Analyst Blog

Progenics: Inexpensive Way To Win Big 3 Potential Ways

Progenics: Inexpensive Way To Win Big Three Potential Ways

Sector Update: Health Care Shares Flat in Pre-Market Trade

Sector Update: Health Care

Progenics' Azedra Found Positive in Phase II Follow-Up Data - Analyst Blog

Progenics' Azedra Found Positive in Phase II Follow-Up Data - Analyst Blog

Sector Update: Health Care Stocks Dropping; Early Progenic Gains Slip Away Despite Data Supporting M

Sector Update: Health Care Stocks Dropping; Early Progenic Gains Slip Away Despite Data Supporting More Testing of Cancer Drug

See More PGNX News...

PGNX's Top Competitors

PGNX $4.61 (1.10%)
Current stock: PGNX
AMGN $147.25 (2.51%)
Current stock: AMGN
GILD $107.18 (1.03%)
Current stock: GILD
BIIB $316.06 (2.26%)
Current stock: BIIB